Publications by authors named "Daling Dong"
Article Synopsis
- The text addresses a correction to a previously published article in the journal, specifically regarding its DOI.
- The correction likely involves updates or modifications to the original content, which could impact the research findings or conclusions.
- Readers are encouraged to refer to the updated article with the specified DOI for the most accurate information.
Background: The primary objective of this study is to thoroughly investigate the intricate correlation between postoperative molecular residual disease (MRD) status in individuals diagnosed with stage I-IIIA non-small cell lung cancer (NSCLC) and clinicopathological features, gene mutations, the tumour immune microenvironment and treatment effects.
Methods: The retrospective collection and analysis were carried out on the clinical data of ninety individuals diagnosed with stage I-IIIA NSCLC who underwent radical resection of lung cancer at our medical facility between January 2021 and March 2022. The comprehensive investigation encompassed an evaluation of multiple aspects including the MRD status, demographic information, clinicopathological characteristics, results from genetic testing, the tumor immune microenvironment, and treatment effects.
Article Synopsis
- ALK-rearranged lung adenocarcinomas with concurrent TP53 mutations show more unstable genetic features, lower effectiveness of ALK-targeted therapies, and worse patient outcomes compared to those without TP53 mutations.
- A study analyzed 155 patients with ALK/RET/ROS1 fusions, revealing that TP53 mutations occurred most often (31%) along with other genetic variations like CDKN2A/B loss, impacting tumor characteristics and immune response.
- Findings indicate that patients with these co-occurring mutations experience higher tumor mutation burdens, more neoantigens, an immunosuppressive tumor environment, and reduced overall survival rates.